SCHEMBL6490655

SCHEMBL6490655

CS(=O)(=O)OCc1ncc(Cl)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.40
LMNA P02545 2/20 0.40
TDP1 Q9NUW8 1/20 0.37
CYP2C9 P11712 2/20 0.35
TSHR P16473 1/20 0.35
APEX1 P27695 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPK1 P28482 1/20 0.34
GAA P10253 1/20 0.34
PKM P14618 1/20 0.34
PTGS1 P23219 3/20 0.33
PTGS2 P35354 3/20 0.33
MCHR1 Q99705 2/20 0.32
SCN9A Q15858 1/20 0.32
HSD17B10 Q99714 3/20 0.32
KMT2A Q03164 3/20 0.32
HTT P42858 2/20 0.32
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12415416 0.85 TRPM8 (0.34) L3MBTL1TDP1MAPK1GAAPKM
SCHEMBL16728654 0.84 PLAU (0.34) L3MBTL1TDP1TSHRGAAPKM
SCHEMBL30486626 0.84 PLAU (0.34) L3MBTL1LMNAPTGS1PTGS2PLAU
SCHEMBL22493674 0.84 PLAU (0.34) L3MBTL1LMNAPTGS1PTGS2PLAU
SCHEMBL6501465 0.81 ALDH1A1 (0.38) L3MBTL1LMNATDP1TSHRSMN1; SMN2
SCHEMBL1722950 0.80 L3MBTL1 (0.58) L3MBTL1LMNATDP1SMN1; SMN2MAPK1
SCHEMBL6487877 0.77 NPC1 (0.39) SMN1; SMN2HSD17B10
SCHEMBL30943933 0.77 CYP17A1 (0.35) SCN9A
SCHEMBL22912582 0.77 L3MBTL1 (0.41) L3MBTL1LMNATDP1CYP2C9TSHR
SCHEMBL17979071 0.77 ALDH1A1 (0.33) L3MBTL1LMNAPTGS1PTGS2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A L3MBTL1 4532/4885LMNA 2742/4885TDP1 948/4885
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD L3MBTL1 790/4885LMNA 3711/4885TDP1 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.